Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
ViroMissile, Inc.
MacroGenics
City of Hope Medical Center
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
Valo Therapeutics Oy
Epkin
Guangzhou FineImmune Biotechnology Co., LTD.
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Columbia University
Ipsen
Xencor, Inc.
Prelude Therapeutics
Pfizer
National Cancer Institute (NCI)
Adaptimmune
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Prelude Therapeutics
Sumitomo Pharma America, Inc.
Emory University
M.D. Anderson Cancer Center
Tempest Therapeutics
Prelude Therapeutics
Quadriga Biosciences, Inc.
Roswell Park Cancer Institute
MacroGenics
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Celgene
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Tocagen Inc.
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Merrimack Pharmaceuticals
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Medical University of South Carolina
Virginia Commonwealth University
Altor BioScience
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics